Monte Rosa (GLUE) CSO sells 3,000 shares after exercising options

Rhea-AI Filing Summary

Monte Rosa Therapeutics Chief Scientific Officer Sharon Townson reported an option exercise and share sale in company stock. On June 23, 2026, she exercised options to acquire 3,000 shares of common stock at $6.14 per share and sold 3,000 shares at $20.00 per share in an open-market transaction.

After these transactions, she directly owned 67,845 shares of common stock and held 203,290 stock options exercisable at $6.14 per share, expiring on April 12, 2031. The filing notes that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2026.

Insider Trade Summary 10b5-1

Net Seller: 3,000 shares ($60,000)

Net Sell 3 txns

Insider Townson Sharon

Role Chief Scientific Officer

Sold 3,000 shs ($60K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	3,000	$0.00	--
Exercise	Common Stock	3,000	$6.14	$18K
Sale	Common Stock	3,000	$20.00	$60K

Holdings After Transaction: Stock Option (Right to Buy) — 203,290 shares (Direct, null); Common Stock — 70,845 shares (Direct, null)

Footnotes (1)

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. The shares underlying this option are fully vested and exercisable.

Key Figures

Shares sold: 3,000 shares Sale price: $20.00 per share Options exercised: 3,000 shares +4 more

7 metrics

Shares sold 3,000 shares Open-market sale of common stock on June 23, 2026 at $20.00

Sale price $20.00 per share Price for 3,000 GLUE shares sold on June 23, 2026

Options exercised 3,000 shares Common stock acquired via option exercise on June 23, 2026

Exercise price $6.14 per share Stock option exercise price for 3,000 underlying GLUE shares

Shares owned after 67,845 shares Direct GLUE common stock holdings following transactions

Options remaining 203,290 options Stock options outstanding after 3,000-share exercise

Option expiration April 12, 2031 Expiration date of the stock option series exercised in part

Key Terms

Rule 10b5-1 trading plan, Stock Option (Right to Buy), derivative security, Chief Scientific Officer

4 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) with 3,000 underlying shares of Common Stock."

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

Chief Scientific Officer other

"Townson Sharon serves as Chief Scientific Officer of Monte Rosa Therapeutics, Inc."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 04:05 PM Accepted by SEC EDGAR 06/25/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Townson Sharon

(Last) (First) (Middle)

MONTE ROSA THERAPEUTICS, INC.

321 HARRISON AVENUE, SUITE 900

(Street)

BOSTON MASSACHUSETTS 02118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monte Rosa Therapeutics, Inc. [ GLUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/23/2026		M(1)		3,000	A	$6.14	70,845	D
Common Stock	06/23/2026		S(1)		3,000	D	$20	67,845	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.14	06/23/2026		M(1)			3,000	(2)	04/12/2031	Common Stock	3,000	$0	203,290	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

2. The shares underlying this option are fully vested and exercisable.

	/s/ Phil Nickson, Attorney-in-Fact	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)